Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations
Pediatric Pulmonology · 2024
DOI: 10.1002/ppul.27211 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pediatric Pulmonology, 2024. Verfasst von Valentina Fainardi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, Cystic Fibrosis Unit, Pediatric Clinic, Parma, Italy. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Aminophenols, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Introduction
The triple combination of elexacaftor/tezacaftor/ivacaftor (ETI) has dramatically improved the outcome of people with Cystic Fibrosis (pwCF) with at least one F508del mutation. However, carriers of rare cystic fibrosis transmembrane conductance regulator (CFTR) variants are not candidates for this innovative treatment.
Methods
In this observational study, we report the results of the compassionate use of ETI in 10 pwCF carriers of rare mutations after 2 months of treatment. Rectal organoids and short‐term cultures of nasal epithelium obtained from rectal suction biopsies and nasal brushing were obtained from four subjects.
Results
After 2 months of ETI, all patients (4 males, mean age 30.1 ± 13.3 years) showed a significant increase of FEV 1 % predicted values [+8.0 (3.5–12.7) %, p < 0.010], body mass index [+0.85 (0–1.22) kg/m 2 , p < 0.020] and cystic fibrosis questionnaire‐revised [+19.5 (6.3–29.2) points, p < 0.009]. A significant decrease of sweat chloride concentration [–11.2 (–1.7 to −34.0) mmol/L, p < 0.020] and exacerbations [–1.5 (–2 to –1), p < 0.008] was also recorded. Overall, 7 out of 10 participants were considered full responders. All patients reported cough disappearance ( n = 3) or reduction ( n = 7). Long‐term oxygen was discontinued in two out of three patients and one also stopped noninvasive ventilation and was removed from the lung transplantation waiting list.
Conclusions
Despite the limited number of cases, our results support the use of CFTR modulators in patients with rare CFTR variants that are not currently approved for ETI in Europe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, Cystic Fibrosis Unit, Pediatric Clinic, Parma, Italy.
- UOSD Centro Fibrosi Cistica, IRCCS Istituto Giannina Gaslini, Genova, Italy.
- Cystic Fibrosis Laboratory D. Lissandrini, Department of Medicine, Division of General Pathology, University of Verona, Verona, Italy.
- Cystic Fibrosis Centre, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
- IRCCS Istituto Giannina Gaslini, UOC Genetica Medica, Genova, Italy.
- Cystic Fibrosis Unit, Pediatric Clinics, University Hospital of Parma, Parma, Italy.
ORCID-Profile: Claudio Sorio, Michela Deolmi
Förderung
- None
Zitieren
APA
Fainardi, V., Cresta, F., Sorio, C., Melotti, P., Pesce, E., Deolmi, M., Longo, F., Karina, K., Esposito, S., & Pisi, G. (2024). Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27211
Vancouver
Fainardi V, Cresta F, Sorio C, Melotti P, Pesce E, Deolmi M, et al. Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations. Pediatric Pulmonology. 2024. doi:10.1002/ppul.27211
BibTeX
@article{Fainardi2024,
author = {Fainardi, Valentina and Cresta, Federico and Sorio, Claudio and Melotti, Paola and Pesce, Emanuela and Deolmi, Michela and Longo, Francesco and Karina, Kleinfelder and Esposito, Susanna and Pisi, Giovanna},
title = {Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations},
journal = {Pediatric Pulmonology},
year = {2024},
doi = {10.1002/ppul.27211}
}
EUVIMED